Results 31 to 40 of about 10,751 (182)

Large Skin Ulcer and Delayed Wound Healing around a Colostomy in a Patient with Metastatic Colorectal Cancer Receiving Vascular Endothelial Growth Factor Receptor-2 Inhibitor Therapy

Case Reports in Oncology, 2019
Ramucirumab is an antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGF)-2 that has been approved for second-line treatment of patients with metastatic colorectal cancer.
Koichi Taira, Yuji Nadatani, Shinji Hirano, Kiyoshi Maeda, Yasuhiro Fujiwara   +4 more
doaj   +1 more source

Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein

, 2021
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-induced deaths worldwide, and limited therapeutic options are available for patients with advanced disease.
Chia-Jui Yen (151746), Chih-Chieh Yen (11107255)   +1 more
core   +1 more source

Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies

Liver Cancer, 2020
Objective: REACH-2 and REACH were randomized, placebo-controlled, double-blind, multicenter phase 3 trials which showed survival benefits of ramucirumab treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein ...
Chia-Jui Yen, Masatoshi Kudo, Ho-Yeong Lim, Chih-Hung Hsu, Arndt Vogel, Giovanni Brandi, Rebecca Cheng, Ioana Simona Nitu, Paolo Abada, Yanzhi Hsu, Andrew X. Zhu, Yoon-Koo Kang   +11 more
doaj   +1 more source

A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations

, 2021
International audienceAim: Ramucirumab, an anti-VEGFR2 monoclonal antibody, has been approved for the treatment of metastatic gastric and colorectal cancer.
Ternant, David, Ohresser, Marc, Desvignes, Celine, Raoul, William, Lecomte, Thierry, Chautard, Romain, Paintaud, Gilles, Lièvre, Astrid, Marc Ohresser, Céline Desvignes, William Raoul, David Ternant, Astrid Lièvre, Thierry Lecomte, Romain Chautard, Gilles Paintaud   +15 more
core   +1 more source

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. [PDF]

, 2021
BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib ...
Josep M. Llovet, Ogburn, Kenyon D, Widau, Ryan C, Zhu, Andrew X, Richard S. Finn, Galle, Peter R, Yann Touchefeu, Andrew X. Zhu, Ryan C. Widau, Pezet, Denis, Jean‐Marc Phelip, Llovet, Josep M, Guido Stirnimann, Lonardi, Sara, Kenyon D. Ogburn, Tomasek, Jiri, Tsai‐Sheng Yang, Stirnimann, Guido, Sara Lonardi, Kim, Tae-You, Karwal, Mark, Kudo, Masatoshi, Phelip, Jean-Marc, Chunxiao Wang, Liang, Kun, Denis Pezet, Koh, Su-Jin, Jiri Tomasek, Peter R. Galle, Tae‐You Kim, Yang, Tsai-Sheng, Masatoshi Kudo, Su‐Jin Koh, Paolo Abada, Finn, Richard S, Touchefeu, Yann, Wang, Chunxiao, Abada, Paolo, Mark Karwal, Kun Liang   +39 more
core   +2 more sources

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study

Thoracic Cancer, 2022
Background Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non‐small‐cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression.
Masaki Ishida, Kenji Morimoto, Tadaaki Yamada, Shinsuke Shiotsu, Yusuke Chihara, Takahiro Yamada, Osamu Hiranuma, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takayuki Takeda, Koichi Takayama   +11 more
doaj   +1 more source

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

Frontiers in Oncology, 2023
IntroductionIn the REVEL trial, ramucirumab plus docetaxel demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared with placebo plus docetaxel for treatment of metastatic ...
Edward B. Garon, Carla Visseren-Grul, Maria Teresa Rizzo, Tarun Puri, Suresh Chenji, Martin Reck   +5 more
doaj   +1 more source

Reducing tumor invasiveness by ramucirumab and TGF‐β receptor kinase inhibitor in a diffuse‐type gastric cancer patient‐derived cell model

Cancer Medicine, 2021
Background Diffuse‐type gastric cancer (GC) is known to be more aggressive and relatively resistant to conventional chemotherapy. Hence, more optimized treatment strategy is urgently needed in diffuse‐type GC.
Song‐Yi Lee, Seonggyu Byeon, Jihoon Ko, Sujin Hyung, In‐Kyoung Lee, Noo Li Jeon, Jung Yong Hong, Seung Tae Kim, Se Hoon Park, Jeeyun Lee   +9 more
doaj   +1 more source

Ramucirumab: A New Agent for Advanced or Metastatic Gastric Junction Adenocarcinoma [PDF]

, 2019
Ramucirumab (Cyramza®), approved April 21, 2014, is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist with a U.S. Food and Drug Administration (FDA) indication for the treatment of advanced or metastatic gastric/gastroesophageal ...
Smith, Adam, Worden, Rebecca, Hoffert, Jessica, Rasor, Brendon, Stewart, Hannah, Koh, David   +5 more
core   +1 more source

Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials

EClinicalMedicine, 2020
Background: Ramucirumab is a widely used cancer drug having gained six regulatory approvals in various advanced solid tumors. Thus, assessing the risk-benefit profile of such a commonly used drug across multiple tumor types is necessary to inform ...
Sophie Marie Anne Effing, Bishal Gyawali
doaj   +1 more source